Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Key findings Within six months of starting GLP-1 therapy, the rate of hypotensive events increased from 8.7% to 10.2% The increased risk remained significant at 12 months, with hypotensive events rising from 13.6% to 14.3% Adults age 65 and older accounted for 53% of hypotensive events despite representing 37% of the study population Patients with Type 2 diabetes made up 75% of those experiencing hypotensive episodes but only 63% of the overall cohort In secondary analyses, the scientists found that weight loss alone did not explain the increased risk, suggesting other mechanisms of action may be at play Below is a Q&A with study senior author Dr
Simple changes can make a big difference
Positive hybridomas were subcloned 24 times to generate monoclonal stable cell lines
Ozempic (semaglutide) and Wegovy are the same compound at different doses
Individual factorsliver function, kidney health, concurrent medications, and personal tolerancedetermine whether dual therapy is safe and effective for a specific patient
